Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H (HK:2315) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Biocytogen Pharmaceuticals has announced that IDEAYA Biosciences has exercised an exclusive worldwide license for Biocytogen’s bispecific antibody-drug conjugate, IDE034. This move could bring Biocytogen up to $406.5 million in various payments, as IDEAYA plans to advance IDE034 towards an IND submission to the FDA by 2025.
For further insights into HK:2315 stock, check out TipRanks’ Stock Analysis page.